New drug combo shows promise for rare, aggressive uterine cancer

NCT ID NCT05147558

Ongoing Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether combining two drugs, pembrolizumab and lenvatinib, can shrink tumors or slow cancer growth in people with advanced uterine or ovarian carcinosarcoma, a rare and aggressive cancer. About 40 participants will receive the treatment, and researchers will also look for blood markers that might predict how well the cancer responds. The goal is to improve disease control, not to cure the cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED UTERINE CARCINOSARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ovarian carcinosarcoma uterine carcinosarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED UTERINE CARCINOSARCOMA UTERINE CARCINOSARCOMA

Contacts and locations

Locations

Memorial Sloan Kettering Basking Ridge (Limited protocol activities)

Basking Ridge, New Jersey, 07920, United States
Memorial Sloan Kettering Bergen (Limited protocol activities)

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Memorial Sloan Kettering Monmouth (Limited protocol activities)

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Nassau (Limited protocol activities)

Rockville Centre, New York, 11553, United States
Memorial Sloan Kettering Suffolk- Commack (Limited Protocol Activities)

Commack, New York, 11725, United States
Memorial Sloan Kettering Westchester (Limited protocol activities)

Harrison, New York, 10604, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.